Renal denervation
A catheter procedure targeting renal nerves to lower blood pressure.
Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 9, 11, 7, 23, 10.
New guidelines and consensus this year
- An expert consensus statement on renal denervation for the management of hypertension endorsed by the Portuguese Association of Interventional Cardiology of the Portuguese Society of Cardiology (APIC-SPC) and the Portuguese Society of Hypertension (SPH)Rev Port Cardiol2026 Aug
- Guidelines for the appropriate use of renal denervation systems in Japan: endorsed by the Japanese Society of Hypertension (JSH), the Japanese Association of Cardiovascular Intervention and Therapeutics (CVIT), and the Japanese Circulation Society (JCS), and their positioning in the JSH 2025 guidelinesHypertens Res2026 Jun
- The expert position of the Polish Cardiac Society, the Polish Society of Hypertension, and the Polish Society of Nephrology on renal denervationKardiol Pol2026
- Renal Denervation in Asia: 2025 Asia Renal Denervation Consortium (ARDeC) Consensus Statement Endorsed by the Hypertension Cardiovascular Outcome Prevention and Evidence in Asia (HOPE Asia) NetworkHypertension2026 Jan
- The role of renal denervation for the treatment of hypertension in patients with chronic kidney disease: a position paper of the Italian Society of NephrologyJ Nephrol2025 Nov
All papers from the last 12 months
221 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Assessment of the safety and effectiveness of catheter-based renal denervation with the symplicity spyral system in patients with resistant hypertension: A single-center experienceClin Exp Hypertens2026 Dec 31PMID 41568449
- Laparoscopic Renal Denervation and Perirenal Adipose Tissue Debulking for Refractory Hypertension in End-Stage Renal DiseaseJACC Case Rep2026 Oct 16PMID 42886134
- Percutaneous Renal Denervation for Resistant Hypertension in a High-Risk Real-World Population: Preliminary Results From a Prospective Single-Center ExperienceCatheter Cardiovasc Interv2026 Oct 15PMID 42876404Review
- Pulsed field ablation with Renal denervation for persistent Atrial fibrIllation: Rationale and design of the PRAISE-AF randomized trialAm Heart J2026 Oct 11PMID 42860163
- Ultrasound renal denervation for treatment-resistant hypertension with severe left ventricular hypertrophyHypertens Res2026 Oct 10PMID 42855522
- Comparative Efficacy of Treatments for Resistant or Uncontrolled Hypertension: A Network Meta-Analysis of Randomized TrialsJACC Adv2026 Oct 5PMID 42832922
- Optimizing Blood Pressure Care in Patients With Resistant Hypertension: 2026 ACC Expert Consensus Decision Pathway: A Report of the American College of Cardiology Solution Set Oversight CommitteeJ Am Coll Cardiol2026 Oct 5PMID 42831847Review
- Combined hepatorenal denervation for hypertension and cardiometabolic disease: a first-in-human studyEur Heart J2026 Oct 5PMID 42319791
- Resistant Hypertension: State of the Art ReviewClin J Am Soc Nephrol2026 Oct 2PMID 42826060
- Reframing renal denervation: from blood pressure reduction to autonomic disease modification-a state-of-the-art reviewClin Hypertens2026PMID 42846707Review
More cardiology trends
All specialties →Inclisiran
An siRNA drug that lowers LDL cholesterol by reducing PCSK9 production in the liver.
Key point: Inclisiran achieves similar LDL-C reductions with biannual dosing, potentially improving adherence, though cardiovascular outcome data are pending.
Factor XI inhibitors
A newer class of anticoagulants that target factor XI or XIa.
Key point: Adding an FXIa inhibitor to standard antiplatelet therapy after acute noncardioembolic ischemic stroke or TIA reduces stroke recurrence without evidence of increased bleeding risk.
Colchicine in cardiovascular disease
Colchicine as an anti-inflammatory therapy in coronary and cardiovascular disease.
Key point: Low-dose colchicine has demonstrated modest reductions in cardiovascular events, although results across trials have been inconsistent.
Intravascular lithotripsy
Shockwaves delivered through a balloon catheter to crack calcium in arteries.
New antihypertensive drugs
New blood pressure drugs, including aldosterone synthase inhibitors and zilebesiran.
Key point: Aldosterone-targeted therapies, including aldosterone-synthase inhibitors and spironolactone, provide clinically meaningful systolic blood pressure reductions in resistant hypertension without increasing serious adverse events.
CETP inhibitors
Drugs that block cholesteryl ester transfer protein, studied for lowering LDL cholesterol.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
"renal denervation"[tiab]Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.